SAMSARA BIOCAPITAL, LLC
Top Portfolio Positions
22 positions ·
$1,029,108,406 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
6,897,652 | $339,088,572 | 32.95% | |
| MLYS |
Mineralys Therapeutics, Inc.
Healthcare
|
5,871,018 | $159,045,877 | 15.45% | |
| ALMS |
Alumis Inc.
Healthcare
|
6,345,219 | $139,785,174 | 13.58% | |
| SEPN |
Septerna, Inc.
Healthcare
|
3,149,128 | $75,673,545 | 7.35% | |
| KLRS |
Kalaris Therapeutics, Inc.
Healthcare
|
12,948,081 | $74,710,427 | 7.26% | |
| SGP |
SpyGlass Pharma, Inc.
Healthcare
|
2,109,953 | $54,668,882 | 5.31% | |
| NGNE |
Neurogene Inc.
Healthcare
|
1,717,127 | $34,617,280 | 3.36% | |
| IVA |
Inventiva S.A.
Healthcare
|
5,194,805 | $28,831,167 | 2.80% | |
| STRO |
Sutro Biopharma, Inc.
Healthcare
|
1,062,872 | $26,476,141 | 2.57% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
968,798 | $13,611,611 | 1.32% |
Portfolio Trend
24 quarters · across all stocks
Holdings in GOSS
Shares Held
Position Value (USD)
11 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,376,221 | 7,222,559 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $22,389,932 | 7,222,559 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $16,122,604 | 6,130,268 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,540,229 | 6,130,268 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $6,743,294 | 6,130,268 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $5,547,892 | 6,130,268 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $6,044,444 | 6,130,268 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $5,523,371 | 6,130,268 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $7,233,716 | 6,130,268 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $5,596,934 | 6,130,268 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $5,106,513 | 6,130,268 | Shares | Sole | 2023-11-14 | |
| No 13F history on record for this holder in this stock. | ||||||